Q1 2023 Results

Company overview Financial review Conclusions Appendix References Kisqali® NATALEE study met its primary endpoint demonstrating clinically meaningful iDFS benefit in broad eBC population INNOVATION KisqaliⓇ (400mg) plus ET significantly reduced the risk of disease recurrence (vs. standard ET alone) Data to be presented at an upcoming medical meeting 30-60% of people with stage II and III eBC treated with ET alone remain at risk of BC recurrence Consistent benefit in a broad population of stage II and III eBC patients at risk of recurrence, including those with no nodal involvement Worldwide regulatory submissions on track for H2 2023 400mg dose used to reduce dose-dependent AEs given tolerability profile of treatment is critical in early breast cancer eBC - early breast cancer. ET endocrine therapy. iDFS-invasive disease free survival. 7 Investor Relations | Q1 2023 Results NOVARTIS | Reimagining Medicine

View entire presentation